Merel van Andel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Merel van Andel has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
- Annemieke C. Heijboer
Amsterdam Gastrointestinal Endocrinology Metabolism, 1105 AZ Amsterdam, The Netherlands
3 shared publications - Madeleine L. Drent
Amsterdam UMC, Dept Internal Med, Endocrine Sect, Boelelaan 1117, NL-1081 HV Amsterdam, Netherlands
2 shared publications - Natasja M. van Schoor
Epidemiology and Data Science, Amsterdam UMC location Vrije Universiteit Amsterdam, Amsterdam, The Netherlands
2 shared publications - Alberto Martin Pereira
Department of Endocrinology and Metabolism, Amsterdam University Medical Center, Amsterdam, the Netherlands
1 shared publication - Aline M E Stades
Department of Vascular Medicine and Endocrinology, University Medical Center Utrecht , 3508 GA Utrecht
1 shared publication - Amir H. Zamanipoor Najafadabadi
Department of Ophthalmology, Leiden University Medical Center , Leiden, ZA 2333
1 shared publication
Latest Publications
- Open Access
- 13 August 2026
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
The Dutch prolactinoma cohort studies: cross-sectional analysis of females focusing on the patient's perspective
Purpose: To assess the results of patient-reported outcome measures (PROMs) by disease activity in a national cohort of females with a prolactinoma. Methods: Females with prolactinoma included in the PRolaCT or ProlaC study were assessed cross-sectionally, comparing patients with active (prolactin above upper limit of normal [ULN]) and controlled (prolactin < ULN) disease. Disease and treatment characteristics were reported. Patients completed PROMs on symptoms (modified PRO-CTCAE), health-related quality of life (HR-QoL) (SF-36), anxiety and depressive symptoms (Hospital Anxiety and Depression Scale (HADS)), and disease burden (Leiden Bother and Needs Questionnaire for patients with Pituitary disease [LBNQ-Pituitary]). Results: A total of 450 females with a prolactinoma were included (active: n = 223, controlled: n = 227); most (97.0%) were treated with dopamine agonists (DAs). Fatigue was the most prevalent symptom in both patients with active and controlled disease (92.6%, and 86.4%, respectively) followed by concentration problems (79.0%, and 64.5%, respectively) (modified PRO-CTCAE, LBNQ-Pituitary). Anxiety and depressive symptoms were worse in patients with active compared to controlled disease (HADS-Anxiety: 8.0 ± 4.5 vs 6.4 ± 4.5 P < .001. HADS-Depression: 6.4 ± 5.0 vs 4.7 ± 4.4 P < .001). Disease burden was higher in patients with active compared to controlled disease (LBNQ-Pituitary: Total Bother 24.4 ± 22.9 vs 16.4 ± 17.9; P < .001). Conclusion: Females with a prolactinoma were most affected by fatigue and cognitive complaints. Although patients with active disease perceived more burden than patients with controlled disease, symptoms including fatigue and psychological and cognitive complaints were prevalent despite disease control. Therefore, improvement of treatment and rehabilitation strategies is needed.
- 13 August 2026
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
Open AccessThe Dutch prolactinoma cohort studies: cross-sectional analysis of females focusing on the patient's perspective
Purpose: To assess the results of patient-reported outcome measures (PROMs) by disease activity in a national cohort of females with a prolactinoma. Methods: Females with prolactinoma included in the PRolaCT or ProlaC study were assessed cross-sectionally, comparing patients with active (prolactin above upper limit of normal [ULN]) and controlled (prolactin < ULN) disease. Disease and treatment characteristics were reported. Patients completed PROMs on symptoms (modified PRO-CTCAE), health-related quality of life (HR-QoL) (SF-36), anxiety and depressive symptoms (Hospital Anxiety and Depression Scale (HADS)), and disease burden (Leiden Bother and Needs Questionnaire for patients with Pituitary disease [LBNQ-Pituitary]). Results: A total of 450 females with a prolactinoma were included (active: n = 223, controlled: n = 227); most (97.0%) were treated with dopamine agonists (DAs). Fatigue was the most prevalent symptom in both patients with active and controlled disease (92.6%, and 86.4%, respectively) followed by concentration problems (79.0%, and 64.5%, respectively) (modified PRO-CTCAE, LBNQ-Pituitary). Anxiety and depressive symptoms were worse in patients with active compared to controlled disease (HADS-Anxiety: 8.0 ± 4.5 vs 6.4 ± 4.5 P < .001. HADS-Depression: 6.4 ± 5.0 vs 4.7 ± 4.4 P < .001). Disease burden was higher in patients with active compared to controlled disease (LBNQ-Pituitary: Total Bother 24.4 ± 22.9 vs 16.4 ± 17.9; P < .001). Conclusion: Females with a prolactinoma were most affected by fatigue and cognitive complaints. Although patients with active disease perceived more burden than patients with controlled disease, symptoms including fatigue and psychological and cognitive complaints were prevalent despite disease control. Therefore, improvement of treatment and rehabilitation strategies is needed.
- Open Access
- 19 September 2024
- Published by Elsevier in Psychoneuroendocrinology
- Vol. 170, 107190
Leptin, ghrelin and high-molecular-weight adiponectin in relation to anxiety in older adults
- 19 September 2024
- Published by Elsevier in Psychoneuroendocrinology
- Vol. 170, 107190
Open AccessLeptin, ghrelin and high-molecular-weight adiponectin in relation to anxiety in older adults
- Open Access
- 25 September 2021
- Published by Elsevier in Journal of Affective Disorders
- Vol. 296, 103-110
Ghrelin, leptin and high-molecular-weight adiponectin in relation to depressive symptoms in older adults: Results from the Longitudinal Aging Study Amsterdam
- 25 September 2021
- Published by Elsevier in Journal of Affective Disorders
- Vol. 296, 103-110
Open AccessGhrelin, leptin and high-molecular-weight adiponectin in relation to depressive symptoms in older adults: Results from the Longitudinal Aging Study Amsterdam
- 24 May 2020
- Published by Oxford University Press (OUP) in The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences
- Vol. 76 (1) , 131-140
The Association Between High-Molecular-Weight Adiponectin, Ghrelin and Leptin and Age-Related Cognitive Decline: Results From Longitudinal Aging Study Amsterdam
Background: Age-related cognitive decline has large-scale functional and economic consequences and understanding its’ pathophysiological mechanisms is therefore essential. Previous research has suggested associations between hormones adiponectin, ghrelin and leptin and neurodegenerative disease. However, their association with age-related cognitive decline has not been fully described. We examine the association between serum high-molecular-weight (HMW) adiponectin, ghrelin and leptin and age-related cognitive decline in older adults.Methods: The associations between HMW adiponectin, ghrelin and leptin and the Mini-Mental-State-Examination, Coding task (Coding), 15 Words Test (15WT) and composite Z-score (general cognitive function) were analyzed by means of a sex-stratified multivariable linear regression analysis in a population-based cohort of 898 older adults at baseline and after 3 years of follow-up.Results: In women, we found a positive association between HMW adiponectin and general cognitive function at baseline (fully adjusted model composite Z-score standardized regression co-efficient beta [β] = .089, p = .025). After 3 years of follow-up, HMW adiponectin was associated with more decline in general cognitive function and information processing speed (fully adjusted model composite Z-score β = −.123, p = .018; Coding β = −.116, p = .027). Ghrelin and leptin were significantly associated with memory in a baseline subgroup analysis of older women. For men, we found no significant associations at baseline or follow-up.Conclusion: Our results show variable associations between hormones HMW adiponectin, ghrelin and leptin and age-related cognitive decline in women but not in men. As there was no clear trend, all our results should be interpreted with caution.
- 24 May 2020
- Published by Oxford University Press (OUP) in The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences
- Vol. 76 (1) , 131-140
The Association Between High-Molecular-Weight Adiponectin, Ghrelin and Leptin and Age-Related Cognitive Decline: Results From Longitudinal Aging Study Amsterdam
Background: Age-related cognitive decline has large-scale functional and economic consequences and understanding its’ pathophysiological mechanisms is therefore essential. Previous research has suggested associations between hormones adiponectin, ghrelin and leptin and neurodegenerative disease. However, their association with age-related cognitive decline has not been fully described. We examine the association between serum high-molecular-weight (HMW) adiponectin, ghrelin and leptin and age-related cognitive decline in older adults.Methods: The associations between HMW adiponectin, ghrelin and leptin and the Mini-Mental-State-Examination, Coding task (Coding), 15 Words Test (15WT) and composite Z-score (general cognitive function) were analyzed by means of a sex-stratified multivariable linear regression analysis in a population-based cohort of 898 older adults at baseline and after 3 years of follow-up.Results: In women, we found a positive association between HMW adiponectin and general cognitive function at baseline (fully adjusted model composite Z-score standardized regression co-efficient beta [β] = .089, p = .025). After 3 years of follow-up, HMW adiponectin was associated with more decline in general cognitive function and information processing speed (fully adjusted model composite Z-score β = −.123, p = .018; Coding β = −.116, p = .027). Ghrelin and leptin were significantly associated with memory in a baseline subgroup analysis of older women. For men, we found no significant associations at baseline or follow-up.Conclusion: Our results show variable associations between hormones HMW adiponectin, ghrelin and leptin and age-related cognitive decline in women but not in men. As there was no clear trend, all our results should be interpreted with caution.
- 1 February 2017
- Published by Elsevier in Clinica Chimica Acta
- Vol. 465, 30-33
A method comparison of total and HMW adiponectin: HMW/total adiponectin ratio varies versus total adiponectin, independent of clinical condition
- 1 February 2017
- Published by Elsevier in Clinica Chimica Acta
- Vol. 465, 30-33
A method comparison of total and HMW adiponectin: HMW/total adiponectin ratio varies versus total adiponectin, independent of clinical condition